Skip Navigation



Annals of Oncology Advance Access published online on October 27, 2005
Annals of Oncology, doi:10.1093/annonc/mdj029
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/1/74    most recent
mdj029v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Del Mastro, L.
Right arrow Articles by Venturini, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Del Mastro, L.
Right arrow Articles by Venturini, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received July 21, 2005
Revised August 31, 2005
Accepted August 31, 2005

original article

Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients

L. Del Mastro 1*, T. Catzeddu 1, L. Boni 2, C. Bell 3, M. R. Sertoli 4, C. Bighin 1, M. Clavarezza 1, D. Testa 5, and M. Venturini 1

1 Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
2 Sperimentazioni Cliniche Controllate, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
3 Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stanford University Cancer Center, Stanford, California
4 Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Università degli Studi, Genova, Italy
5 Laboratorio Endocrinologia Azienda Ospedaliera S. Martino, Genova, Italy

* To whom correspondence should be addressed.
L. Del Mastro, E-mail: lucia.delmastro{at}istge.it


  Abstract

Background: Standard methods to prevent chemotherapy-induced early menopause in young, breast cancer patients are unavailable to date. Preclinical data has suggested that luteinising hormone-releasing hormone (LH-RH) analogs given during treatment can decrease the gonado-toxicity induced by chemotherapy. This phase II study aimed to assess the activity of such a method in young, breast cancer patients undergoing adjuvant chemotherapy.

Patients and methods: Premenopausal patients received the LH-RH analog goserelin 3.6 mg every 4 weeks before and during chemotherapy. According to two-stage optimal phase II Simon design, treatment was considered clinically interesting if it was able to prevent menopause in 19 out of 29 patients of the study population. The resumption of ovarian function was defined by a resumption of menstrual activity or by a follicle-stimulating hormone (FSH) value ≤40 IU/l within 12 months after the last cycle of chemotherapy.

Results: Thirty patients were enrolled and 29 were evaluable. Median age was 38 years (range 29-47). All but one patient received CEF regimen (cyclophosphamide, epirubicin, 5-fluorouracil). Resumption of menstrual activity was observed in 21 patients (72%; 95% CI 52% to 87%) and a FSH value ≤40 IU/l in 24 patients (83%; 95% CI 63% to 93%). Menses resumption was observed in 16 out of 17 patients (94%) with age <40 years and in five out of 12 patients (42%) with age ≥40 years.

Conclusion: Goserelin given before and during chemotherapy may prevent premature menopause in the majority of patients. The different success rate by age, however, indicates the need of a prospective evidence of the efficacy of such a strategy.

Keywords: breast cancer; early menopause; fertility preservation.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 In VivoHome page
T. MALTARIS, M. W. BECKMANN, and R. DITTRICH
Fertility Preservation for Young Female Cancer Patients
In Vivo, January 1, 2009; 23(1): 123 - 130.
[Abstract] [Full Text] [PDF]

Home page
 ReproductionHome page
M. L Meistrich and G. Shetty
Hormonal suppression for fertility preservation in males and females
Reproduction, December 1, 2008; 136(6): 691 - 701.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
R. Beck-Fruchter, A. Weiss, and E. Shalev
GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data
Hum. Reprod. Update, November 1, 2008; 14(6): 553 - 561.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
Z. Blumenfeld and M. von Wolff
GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy
Hum. Reprod. Update, November 1, 2008; 14(6): 543 - 552.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
H. C. F. Moore
Ovarian Failure after Chemotherapy for Breast Cancer and the Role of Gonadotropin-releasing Hormone Analogs in Protection of Ovarian Function
ASCO Educational Book, January 1, 2008; 2008(1): 39 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Kaufmann, G. von Minckwitz, H. D. Bear, A. Buzdar, P. McGale, H. Bonnefoi, M. Colleoni, C. Denkert, W. Eiermann, R. Jackesz, et al.
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
Ann. Onc., December 1, 2007; 18(12): 1927 - 1934.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
Z. Blumenfeld
How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries
Oncologist, September 1, 2007; 12(9): 1044 - 1054.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. Oktay, M. Sonmezer, O. Oktem, K. Fox, G. Emons, and H. Bang
Absence of Conclusive Evidence for the Safety and Efficacy of Gonadotropin-Releasing Hormone Analogue Treatment in Protecting Against Chemotherapy-Induced Gonadal Injury
Oncologist, September 1, 2007; 12(9): 1055 - 1066.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Del Mastro and M. Venturini
Fertility Preservation Strategies for Breast Cancer Patients
J. Clin. Oncol., September 1, 2006; 24(25): 4220 - 4221.
[Full Text] [PDF]

Home page
 JCOHome page
K. H. Oktay and S. J. Lee
In Reply
J. Clin. Oncol., September 1, 2006; 24(25): 4221 - 4222.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.